Myocet liposomal (previously Myocet) (doxorubicin)
- Region
- 🇪🇺 EU
- Active substance
- doxorubicin
- Company
- CHEPLAPHARM Arzneimittel GmbH
- Status
- Authorised
- Therapeutic area
- Breast Neoplasms
- CHMP opinion
- Wed 12 Apr 2000
- EU approval
- Thu 13 Jul 2000
- Application
- EMEA/H/C/000297
- ATC
- L01DB01
- Official record
- www.ema.europa.eu
Indication
Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Zolsketil pegylated liposomal Authorised · Accord Healthcare S.L.U.
- 🇺🇸 Oxderys Approved · Avyxa Holdings
- 🇪🇺 Caelyx pegylated liposomal Authorised · Baxter Holding B.V.
- 🇪🇺 Celdoxome pegylated liposomal Lapsed · Baxter Holding B.V.
- 🇪🇺 Doxorubicin Hydrochloride Tillomed Application withdrawn · Laboratorios Tillomed Spain S.L.U
- 🇪🇺 Doxolipad Refused · TLC Biopharmaceuticals B.V.
- 🇪🇺 Doxorubicin SUN Application withdrawn · Sun Pharmaceutical Industries Europe B.V.
Follow Myocet liposomal (previously Myocet)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.